Business | Danaher Corporation to Acquire Masimo for $9.9 Billion
By Newzvia
Quick Summary
Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation, a leading specialty diagnostics provider, for approximately $9.9 billion in cash. This strategic move aims to strengthen Danaher's diagnostics franchise with Masimo's advanced patient monitoring solutions, potentially impacting the global medical technology landscape.
Danaher Corporation to Acquire Masimo for $9.9 Billion
Danaher Corporation announced today its definitive agreement to acquire specialty diagnostics provider Masimo Corporation for approximately $9.9 billion in cash. This strategic acquisition aims to significantly strengthen Danaher's diagnostics segment by integrating Masimo's advanced pulse oximetry and patient monitoring solutions.
Key Details of the Acquisition
Under the terms of the agreement, Danaher will acquire all outstanding shares of Masimo common stock for $180 per share in cash, totaling an enterprise value of approximately $9.9 billion, which includes assumed indebtedness and net of acquired cash. Upon completion of the transaction, Masimo will operate as a standalone company within Danaher's Diagnostics segment. This move is set to enhance Danaher's diagnostics franchise, particularly with Masimo’s trusted brand and differentiated technology in pulse oximetry and other patient monitoring solutions, primarily in acute care settings.
Official Position and Company Statements
Rainer M. Blair, President and Chief Executive Officer of Danaher, expressed excitement about welcoming the Masimo team, noting that the company has been an exceptional strategic fit for Danaher for many years. Julie Sawyer Montgomery, Executive Vice President for Diagnostics at Danaher, added that Masimo's advanced sensor technology and AI-enabled monitoring will bring powerful new capabilities to Danaher's diagnostics portfolio. Katie Szyman, Masimo's Chief Executive, stated that becoming part of Danaher will strengthen Masimo's ability to scale its monitoring technologies globally and accelerate its mission to transform patient care.
Market Reaction and Outlook
Following the announcement, Masimo's shares surged over 34% in premarket trading on , with the stock reaching $175 per share, up from its previous close of $130.15. This valuation reflects a significant premium to its prior closing price. Conversely, Danaher's stock traded over 6% lower after the announcement. Danaher anticipates the transaction to be accretive to adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year following completion. The company also expects to realize over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year.
Timeline and Next Steps
The transaction has been unanimously approved by both Masimo's and Danaher's Boards of Directors. It is anticipated to close in the second half of 2026, subject to customary closing conditions, including applicable regulatory clearances and approval from Masimo shareholders. Danaher plans to fund the acquisition using cash on hand and proceeds from debt financing.
Context and Background
Danaher Corporation is a global science and technology innovator, with a diverse portfolio encompassing biotechnology, life sciences, and diagnostics. Its diagnostics segment is a key area of focus, with previous acquisitions and innovations aimed at improving diagnostic confidence and health outcomes worldwide. Masimo Corporation, headquartered in Irvine, California, is a global medical technology company renowned for developing and marketing noninvasive monitoring technologies, including pulse oximetry, patient monitoring devices, and related software platforms. This acquisition underscores Danaher's ongoing strategy of expanding into high-growth sectors and leveraging strategic acquisitions to gain market share in the evolving healthcare industry.
Key Takeaways
- Danaher Corporation has agreed to acquire Masimo Corporation for approximately $9.9 billion in an all-cash deal.
- Masimo will operate as a standalone business unit within Danaher's Diagnostics segment following the acquisition.
- The acquisition aims to strengthen Danaher's diagnostics offerings with Masimo’s leading pulse oximetry and patient monitoring solutions.
- The transaction is expected to close in the second half of 2026, pending regulatory and shareholder approvals.
- Masimo shares saw a significant surge after the announcement, while Danaher's stock experienced a decline.
People Also Ask
What is the value of Danaher's acquisition of Masimo?
Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for approximately $9.9 billion in cash. This figure represents the total enterprise value, including assumed indebtedness and net of acquired cash.
How will Masimo operate after being acquired by Danaher?
Upon the completion of the acquisition, Masimo Corporation is slated to operate as a standalone company. It will be integrated into Danaher's Diagnostics segment, maintaining its brand and focus on patient monitoring solutions.
What is the primary objective behind Danaher acquiring Masimo?
Danaher's primary objective in acquiring Masimo is to bolster its diagnostics franchise. The acquisition will integrate Masimo's leading pulse oximetry and patient monitoring solutions, enhancing Danaher's capabilities in specialty diagnostics.
What was the market's initial reaction to the Danaher-Masimo acquisition announcement?
The market reacted with a significant surge in Masimo's shares, which jumped over 34% in premarket trading on . In contrast, Danaher's stock experienced a decline of over 6% following the announcement.
Last updated: